Rare Disease Approvals by Therapeutic Area: CDER's Orphan-Designated Novel-Product Count, 2021–2025

This article does not establish a complete FDA-wide count of orphan-designated approval events by indication. The narrower comparison supported by the cited CDER sources is 123 orphan-designated novel drug products approved from January 1, 2021, through December 31, 2025. In an editorial classification of those product entries, oncology and tumor-directed uses form the largest area, with 50 products (40.7%).

Extraction date: October 28, 2026. Approval window: January 1, 2021–December 31, 2025, inclusive. The 123 figure counts product entries—not distinct application-and-orphan-indication pairs, unique active substances, or all FDA regulatory actions.

Table of contents

• What the count represents
• Therapeutic-area comparison
• How therapeutic areas were assigned
• Trends and interpretation limits
• Frequently asked questions
• Sources

What the count represents

Orphan drug designation and marketing approval are separate FDA processes. Designation concerns a drug or biologic intended to treat, prevent, or diagnose a rare disease; it does not itself mean the product has been approved. FDA’s annual CDER reports identify novel products with orphan drug designation, while their annual approval tables provide product names, approval dates, and a summary of the FDA-approved use on the approval date. (FDA orphan-product overview; FDA FAQ on public designation information)

The annual reports list 26, 20, 28, 26, and 23 orphan-designated novel products for 2021 through 2025, respectively. That is 123 of 238 CDER novel product approvals, or 51.7% across the five years. The reports and tables are available for 2021, 2022, 2023, 2024, and 2025.

These figures describe novel products with orphan designation in CDER’s annual reporting. They are not a count of every rare-disease medicine: not every drug for a rare disease necessarily receives orphan designation, and the annual novel-product lists do not capture all supplemental approvals or other regulatory actions. (FDA CDER novel drug approval tables, 2021–2025)

Therapeutic-area comparison

The table assigns one primary editorial area to each of the 123 CDER product entries. Shares use the same denominator of 123 throughout, including the “Other / unclassified” row. Annual counts are shown so the area totals can be checked against the yearly roster counts above.

How therapeutic areas were assigned

The area labels are an editorial classification, not official FDA fields. Each product was classified from the FDA annual table’s summary of its approved use on the approval date, rather than from its mechanism of action. Those summaries are brief and may not capture every condition or use in the full labeling; consult the FDA product record and label for complete use information. (FDA annual novel-approval tables)

To make the table additive, each product receives one primary area. The precedence rule groups malignant and other neoplasm-directed uses—including hematologic neoplasms—in oncology/tumor-directed; non-neoplastic blood and coagulation conditions go to hematology. Other overlapping uses are assigned by the primary disease named in the approved-use summary. For example, myasthenia gravis is classified as neuromuscular, hemophilia as hematology/coagulation, and hereditary angioedema as immunology/allergy.

“Tumor-directed” does not mean every condition in that category is a cancer: Ogsiveo’s indication for desmoid tumors is classified there, although desmoid tumors are noncancerous. (FDA 2023 approval table; National Cancer Institute on desmoid tumors) Some indications span more than one body system, so another reasonable classification could move individual products. No product entry was left unclassified under this broad scheme; the zero-count row is retained for clarity.

Trends and interpretation limits

Oncology/tumor-directed uses are the largest category in each year in this CDER-only comparison. The annual total is not a steady increase: it ranges from 20 products in 2022 to 28 in 2023, followed by 26 in 2024 and 23 in 2025. The share of each year’s CDER novel-product cohort with orphan designation ranges from 50.0% to 54.1%. These are descriptive orphan drug approval trends for the stated product-level proxy, not a complete count of rare-disease approvals.

The FDA’s searchable Orphan Drug Designations and Approvals database provides designation information and, for approved designated products, approval dates and approved indications. But a product roster is not enough to verify every qualifying application-and-indication pair. A product may have multiple designated or approved uses, and its original approval date may concern a different use from a later approved indication. FDA's Orphan Drug Designations and Approvals record for Breyanzi illustrates the distinction: it lists follicular lymphoma as the designated use, a 2021 approval for a different lymphoma indication, and a later 2024 approval for the designated use. Accordingly, this article does not present the 123 products as 123 qualifying orphan-indication approval events.

There is also a center-coverage gap. CDER’s annual series does not supply a comparable FDA-wide roster for CBER-regulated products. FDA publishes separate CBER lists of orphan approvals for new BLAs: the lists contain 5 product entries in 2022, 12 in 2023, 7 in 2024, and 5 in 2025. They are not added to the CDER totals because the published CBER series begins in 2022 and does not provide a comparable 2021 roster. FDA’s Drugs@FDA approval reports also state that the monthly reports cover CDER and exclude CBER-regulated products.

The selected fields in the QOPE FDA Approvals dataset do not provide a complete indication or approval history, so they do not establish the event-level count requested.

These are historical approval records, not a measure of current marketing availability, current label status, disease burden, patient access, unmet need, clinical superiority, or company market share.

Frequently asked questions

Is 123 the number of FDA orphan drug approvals from 2021 to 2025?

No. It is the number of orphan-designated CDER novel product entries in the annual reports for the five-year window. It is not a count of FDA-wide indication-level approval events or all regulatory actions.

Does orphan drug designation mean a product was approved?

No. FDA treats designation and approval as separate processes. Designation alone does not establish that FDA later approved the product or a particular indication. (FDA orphan-product overview)

Why doesn't this article provide a complete FDA-wide table by indication?

The CDER annual reports provide product-level annual rosters, while FDA's separate CBER orphan-approval series starts in 2022. This analysis did not establish a complete, comparable FDA-wide match of each application-and-orphan-indication pair to the qualifying indication's approval date. The table therefore reports a CDER novel-product proxy, not a complete FDA-wide indication-event count.

Where can I check an individual designation or approval?

Use FDA’s Orphan Drug Designations and Approvals database for designation details and Drugs@FDA for relevant approval records. Check the individual FDA record and labeling when the exact indication or current status matters.

Sources

• FDA: Designating an Orphan Product—Drugs and Biological Products
• FDA annual novel drug approval tables: 2021 through 2025.
• National Cancer Institute: Nirogacestat Shrinks Desmoid Tumors